Li Mengtao

[Expert Profile] Li Mengtao, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in systemic lupus erythematosus in China, working in the Department of Rheumatology, Peking Union Medical College Hospital. He has long been dedicated to the clinical diagnosis, treatment, and translational research of difficult rheumatic and autoimmune diseases such as lupus erythematosus, antisynthetase syndrome, and ANCA-associated vasculitis, and is a core scholar in lupus research in China.

[Education & Career] Professor Li Mengtao graduated from Peking Union Medical College, completed systematic clinical and research training in the Department of Rheumatology at PUMCH, and further studied at famous international rheumatology research centers. He studied under senior Chinese rheumatology experts, has long participated in national-level lupus research projects, and holds academic positions including Vice President of the Rheumatology Physicians Branch of the Chinese Medical Doctor Association. He has presided over grants including the National Natural Science Foundation of China, and is an outstanding young and middle-aged leading expert in the field of lupus research with abundant achievements.

[Areas of Expertise] Professor Li specializes in precise diagnosis and stratified treatment of systemic lupus erythematosus, comprehensive treatment of lupus nephritis and lupus crisis, and the diagnosis and treatment of difficult rheumatic diseases such as antisynthetase syndrome and ANCA-associated vasculitis. He has extensive experience in lupus activity assessment and standardized application of immunosuppressive and targeted biologic agents (such as belimumab). He excels at managing "refractory lupus with repeated relapse and multi-organ involvement," helping patients achieve long-term stability and protecting renal function and important organs.

[Academic Achievements & Industry Contributions] As one of the principal investigators, Professor Li has deeply participated in large-scale Chinese systemic lupus erythematosus cohort studies and national multi-center clinical trials, systematically evaluating the efficacy and safety of novel targeted therapies in Chinese lupus patients, with findings published in authoritative domestic and international journals. He has participated in the development of Chinese lupus diagnosis and treatment guidelines and expert consensus statements, actively promoted the popularization of standardized lupus diagnosis and treatment and the concept of whole-course patient management, and organized lupus patient education and grassroots physician training, making important contributions to improving Chinese lupus diagnosis standards and patient outcomes.

[Clinical Practice & Outstanding Contributions] Professor Li has long held dedicated lupus clinics, cumulatively treating tens of thousands of patients with systemic lupus erythematosus and difficult rheumatic diseases, safeguarding fertility hopes and life futures for countless young lupus patients. He values patient education and psychological support, and has repeatedly organized lupus patient rehabilitation camps and science popularization lectures, helping patients correctly understand their conditions and follow standardized treatment. He has been invited to deliver reports at national academic conferences on multiple occasions, and is deeply trusted by patients and recognized by peers alike. He is an outstanding expert in the field of lupus prevention and treatment in China.

[Honors & Reputation] Professor Li Mengtao serves as a standing committee member of the Rheumatology Physicians Branch of the Chinese Medical Doctor Association, among other academic positions. He has presided over national-level projects including the National Key R&D Program, and is a senior expert in the field of rheumatic and autoimmune diseases in China. He has accumulated extensive experience in precise diagnosis and treatment of difficult rheumatic diseases including systemic lupus erythematosus, antisynthetase syndrome, and ANCA-associated vasculitis. He has led research on lupus patient cohorts and prognosis, promoted the implementation of treat-to-target and whole-course management concepts in clinical practice, and has research findings published in authoritative domestic and international journals. For decades on the clinical front lines, he has helped numerous severe lupus patients control their conditions, reduce relapse, and successfully conceive and give birth, and is deeply trusted by patients and respected by peers alike.